BioRestorative Therapies (NASDAQ:BRTX) Announces Earnings Results

BioRestorative Therapies (NASDAQ:BRTX) released its quarterly earnings data on Tuesday. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.06, Yahoo Finance reports. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.03 million. BioRestorative Therapies had a negative return on equity of 96.09% and a negative net margin of 7,303.33%. During the same period in the prior year, the firm posted ($0.77) EPS.

BioRestorative Therapies Price Performance

Shares of BRTX traded up $0.02 during midday trading on Thursday, reaching $1.42. 17,790 shares of the stock were exchanged, compared to its average volume of 1,070,982. BioRestorative Therapies has a twelve month low of $1.03 and a twelve month high of $3.67. The company has a market capitalization of $9.61 million, a price-to-earnings ratio of -0.61 and a beta of 63.47. The business’s 50-day moving average price is $1.69 and its 200 day moving average price is $1.50.

Wall Street Analysts Forecast Growth

Separately, Roth Mkm boosted their price objective on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.